ACADIA Pharmaceuticals recently announced that, following a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) regarding its Rett syndrome treatment Trofinetide, the company plans to formally submit a request for re-examination.
Show original
This decision reflects the company's continued confidence in the potential of the drug and its commitment to seeking new treatment options for the Rett syndrome patient community.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
Goldman Sachs warns that US stocks may need a correction before continuing to rise
AIcoin•2026/03/02 22:41
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$69,374.88
+6.30%
Ethereum
ETH
$2,054.32
+6.66%
Tether USDt
USDT
$1
-0.01%
BNB
BNB
$640.28
+3.96%
XRP
XRP
$1.4
+3.66%
USDC
USDC
$1
+0.01%
Solana
SOL
$88.09
+6.27%
TRON
TRX
$0.2831
+0.88%
Dogecoin
DOGE
$0.09493
+2.71%
Cardano
ADA
$0.2812
+3.28%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now